CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome

CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome

Publication date: Sep 26, 2019

A Phase II, multicenter, double blind, double dummy, randomized, 2 arms parallel study to evaluate the efficacy, safety and pharmacokinetics of CHF6563 in babies with Neonatal Opioid Withdrawal Syndrome

Concepts Keywords
Alcohol Abuse Range investigational site
Aminotransferases Provisions protocol
Antibiotics Maternal alcohol abuse
Bilirubin Hypoxic ischemic encephalopathy
Birth Weight Exclusively Neonatal hypoglycemia
CDC Neonatal respiratory illness
Clinical Trial Antibiotics
Congenital Medical specialties
Congenital Malformations Neonatology
Double Blind Health
Fetal Medicine
Glucose Withdrawal syndrome
Hyperbilirubinemia Neonatal infection
Infection Birth defect
Informed Consent Neonatal encephalopathy
Intravenous Birth weight
Medicinal Product Down syndrome
Neonatal Pharmacokinetics
Neonate Provisions protocol
Opioid
Opioids
Pharmacokinetics
Placebo
Protocol
Randomization
Reference Range
Respiratory Illness
Seizures
Serum
Sublingual
Syndrome
Withdrawal Syndrome

Semantics

Type Source Name
disease MESH infection
disease MESH malformations
disease MESH congenital
disease MESH growth
gene UNIPROT KIDINS220
disease DOID Syndrome
disease MESH Syndrome
disease MESH fetal alcohol spectrum disorders
disease MESH alcohol abuse
disease DOID alcohol abuse
drug DRUGBANK Dextrose unspecified form
disease MESH encephalopathy
disease DOID encephalopathy
disease MESH hypoxic ischemic encephalopathy
disease MESH seizures
disease MESH hyperbilirubinemia
disease DOID hyperbilirubinemia
gene UNIPROT SERPINF2
gene UNIPROT NR4A2
gene UNIPROT ALG3

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *